Scholarly Works

Are P2Y12 inhibitors superior to aspirin for...

Journal article

Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

Authors

Carlin S; Eikelboom J

Journal

Expert Review of Cardiovascular Therapy, Vol. 21, No. 5, pp. 305–309

Publisher

Taylor & Francis

Publication Date

May 4, 2023

DOI

10.1080/14779072.2023.2199155

ISSN

1477-9072

Associated Experts

John Eikelboom

Professor, Faculty of Health Sciences

Labels

Fields of Research (FoR)

32 Biomedical and Clinical Sciences 3201 Cardiovascular medicine and haematology

Sustainable Development Goals (SDG)

3 Good Health and Well Being

Medical Subject Headings (MeSH)

Humans Aspirin Cardiovascular Diseases Secondary Prevention Platelet Aggregation Inhibitors Clopidogrel Purinergic P2Y Receptor Antagonists Receptors, Purinergic P2Y12 Drug Therapy, Combination

View published work (Non-McMaster Users)

View published work (McMaster Users)

Contact the Experts team

Get technical help

or

Provide website feedback